Common Variable Immunodeficiency

Marco Pescador Ruschel; Scott Penney

Common Variable Immunodeficiency

Author: Marco A. Pescador Ruschel Editor: Scott W. Penney Updated: 11/30/2025 6:16:52 PM

Introduction

Common variable immunodeficiency (CVID) represents the most common symptomatic primary immunodeficiency worldwide. The disorder arises from impaired antibody production caused by defects in B cell differentiation and function, often accompanied by abnormalities in T cell compartments and immune regulation.[1][2][3][4] Rather than constituting a single disease, CVID encompasses a heterogeneous group of conditions unified by hypogammaglobulinemia—characterized by reduced serum levels of IgG, typically decreased IgA, and occasionally low IgM—together with poor or absent specific antibody responses to immunizations or infections.[5]

CVID displays marked variability in both clinical and immunological features. Patients frequently present with recurrent sinopulmonary infections, autoimmune manifestations, granulomatous inflammation, increased susceptibility to malignancy, and impaired antibody responses despite a normal or near-normal circulating B cell count.[6][7] The syndrome arises from a spectrum of genetic abnormalities, many of which remain unidentified. The term "variable" highlights the disorder’s broad range of clinical presentations and underlying molecular mechanisms.[6][8]

Etiology

Register For Free And Read The Full Article

Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.

Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities

Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Etiology

The etiology of CVID is highly heterogeneous and multifactorial, involving a complex interplay of genetic, epigenetic, and environmental factors. In most cases, a specific cause cannot be identified, and the disorder is considered idiopathic in 80% to 90% of patients.[4] Despite more than 4 decades of investigation, the primary cause of CVID remains unknown, although genetic contributions are well recognized.[9]

Approximately 20% of CVID patients have a first-degree family member with a selective IgA deficiency, and 15% to 35% of cases are now attributed to monogenic defects, most commonly involving genes critical for B cell development, activation, and survival, such as TNFRSF13B (encoding TACI), NFKB1, NFKB2, ICOS, CD19, and others.[1][10][11] Specific examples include:

Intrinsic B cell defects (CD19 deficiency due to mutations at 16p11.2)
Intrinsic T cell defects (ICOS deficiency from mutations at 2q33)
Mutations in TNF receptors, TACI or BAFFR deficiency from mutations in TNFRSF13B (17p11.2) and TNFRSF13C (22q13.1-q13.31), respectively [9][12][13][14]

Other monogenic defects associated with CVID include deficiencies in MSH5, CD81, and CD20.[14] These mutations may be inherited or occur de novo, with variable penetrance and expressivity even within the same family. Nevertheless, many patients with CVID lack an identifiable genetic mutation.[15][16][11]

CVID is increasingly recognized as a polygenic or oligogenic condition in which multiple low-penetrance variants affecting immune regulatory pathways interact to shape disease susceptibility and phenotype.[1][15][16][11] Epigenetic mechanisms, including DNA methylation changes, histone modifications, and microRNA dysregulation, further influence gene expression and contribute to immune cell dysfunction.[1][2] Most cases of CVID do not follow a clear pattern of inheritance. Documented inheritance modes include autosomal dominant with variable penetrance, autosomal recessive, and, in rare cases, X-linked transmission.

Environmental factors are also suspected to influence disease onset, although no consistent external triggers have been identified.[17] Overall, the pathogenesis of CVID spans a spectrum from monogenic defects to complex immune dysregulation. Abnormalities in B and T cell compartments, disruption of germinal center formation, and altered immune regulatory networks all contribute to the significant clinical and immunological heterogeneity of this disorder.[1][3][16][10][2]

Epidemiology

CVID represents the most frequently diagnosed symptomatic primary immunodeficiency in clinical practice, although it remains rare overall. The estimated prevalence ranges from approximately 1 in 25,000 to 1 in 50,000 individuals in Europe and North America, with higher rates reported in northern Europe.[18][6][19][20][21] Certain Asian populations demonstrate lower prevalence, with Taiwan reporting 0.28 cases per 100,000 individuals.[21]

CVID affects males and females equally, with no apparent racial predilection.[5][22] Onset may occur at any age, but most diagnoses are made after puberty, typically between ages 20 and 45, with peak incidence in the 20- to 40-year range.[6][19][8][5] Early-onset disease in individuals younger than 10 years of age is also recognized, particularly in males.[21] Diagnostic delays remain common, historically averaging 4 to 5 years, though improvements in awareness and immunological testing have shortened this timeframe in recent decades.[21][19]

Most cases arise sporadically, although a minority follow familial patterns. Familial clustering is more common in populations with high consanguinity, where an autosomal recessive inheritance pattern may be suggested. Clinically, CVID presents with substantial heterogeneity, but recurrent sinopulmonary infections remain the most frequent manifestation. Many patients also experience noninfectious complications, eg, autoimmunity, lymphoproliferative disease, enteropathy, and malignancy.[8] These complications contribute to reduced life expectancy, particularly among patients who develop noninfectious manifestations.[8]

Pathophysiology

The pathophysiology of CVID is complex and heterogeneous, reflecting a final common pathway of hypogammaglobulinemia arising from multiple immunoregulatory defects.[6] The central immunologic hallmark of CVID is a defect in B-cell differentiation and function, resulting in impaired production of isotype-switched, affinity-matured antibodies.[2][23] This dysfunction originates from abnormalities in germinal center formation and function, which are essential for generating high-affinity class-switched memory B cells and plasma cells.[2][1][23]

While the number of total B cells is typically normal in many patients, a reduced percentage of isotype-switched memory B cells capable of sustaining long-term antibody responses is noted.[23][24] Immunophenotypically, CVID also features an expansion of CD21^low B cells, indicating a block in B cell maturation and selection.[23] High-throughput immunoglobulin heavy chain sequencing studies have demonstrated decreased V(D)J (variable, diversity, and joining gene segments) recombination diversity and reduced somatic hypermutation, further confirming a defect in antibody maturation.[23][23]

Additional B-cell abnormalities include:

Aberrant gene rearrangement and reduced diversity of the naïve B cell pool [23]
Impaired signaling via Toll-like receptors 7 and 9 (TLR7, TLR9) in B cells and plasmacytoid dendritic cells, leading to diminished cytokine production and humoral responses [25][26][27][28]
[28]Memory B cell subsets correlate with the following clinical features:
- Lower switched memory B cells are linked to splenomegaly, autoimmunity, lymphoid proliferation, and granulomatous disease.
- Low IgM memory B cells associate with bronchiectasis.[24][29][30][31][32][33][34]

In some patients, B-cell defects are apparent as early as the pro-B cell stage, indicating a developmental block that occurs before the formation of germinal centers.[23]

T cell abnormalities are also prominent, especially in patients with noninfectious complications, including:

Reduced T regulatory cells (Tregs) [35]
Increased T follicular helper (Tfh) cells [36]
Loss of TCR repertoire diversity, often associated with thymic involution and failure of thymic output of naïve T cells [37][38]

Additional T cell features reported in CVID include:

Decreased proliferation to mitogens and antigens [6]
Altered CD4/CD8 ratios, often due to CD4⁺ cell decline or CD8⁺ cell expansion [39]
Increased CD26 and CD30 levels (the latter linked to splenomegaly and malignancy) [40]
Impaired T cell receptor signal transduction and reduced IL-12 production by dendritic cells [41]
A drop in plasma cells within the bone marrow and gastrointestinal tract [24]

At the molecular level, monogenic and polygenic defects in genes affecting B cell receptor signaling, costimulation, and intracellular pathways (eg, TNFRSF13B/TACI, ICOS, CD19, NFKB1, and NFKB2) have been implicated in CVID's immunological abnormalities.[2][1][3] Furthermore, epigenetic dysregulation, including alterations in DNA methylation and histone modification, as well as environmental influences (eg, microbial translocation from impaired gut barrier function), may contribute to immune cell dysfunction and clinical heterogeneity.[2][1][37]

History and Physical

Clinical Features

Patients with CVID typically present with a history of recurrent infections, particularly affecting the upper and lower respiratory tracts, including sinusitis, otitis media, bronchitis, and pneumonia, which are often severe, persistent, or unusually frequent.[42][36][21][5] Sinopulmonary infections are common and may lead to bronchiectasis, which contributes to chronic productive cough, dyspnea, and obstructive lung disease.[43][44][45][46][42][21] Common organisms that cause these infections include Haemophilus influenzae, Streptococcus, Moraxella catarrhalis, and Staphylococcus aureus. Less frequently, patients present with septic arthritis, bacterial meningitis, sepsis, cutaneous infections, and, rarely, infections caused by Pneumocystis jirovecii or Mycoplasma pneumoniae.[44][45]

Besides infections, noninfectious complications are common and may be the initial presentation, particularly in adults, including:

Autoimmune cytopenias, eg, immune thrombocytopenia (10%–12%), coombs-positive autoimmune hemolytic anemia (5%–7%), and Evans syndrome [47][48]
Rheumatoid arthritis (1%–10%), typically seronegative due to lack of autoantibody production [49]
Systemic lupus erythematosus (rare with a frequency of <1%, and in some cases, remission correlates with a loss of B cells; flares may occur after the onset of hypogammaglobulinemia) [50]
Autoimmune thyroiditis, Sjögren’s syndrome, vitiligo, sicca syndrome [47][51]

Lymphoproliferative disorders, eg, lymphadenopathy and splenomegaly, often associated with autoimmunity or granulomatous disease, are also characteristic.[43][48] Granulomas may manifest in the lungs as parenchymal nodules or ground-glass opacities.[43][44]

Gastrointestinal symptoms are frequent and heterogeneous, including:

Chronic diarrhea and malabsorption due to Giardia, Clostridium difficile, bacterial enterocolitis, Cytomegalovirus, or Helicobacter pylori infection [44]
Inflammatory bowel-like disease, sprue-like illness, pernicious anemia (10%), protein-losing enteropathy [52]
Symptoms may precede diagnosis and lead to diagnostic delays [42][21]

Skin manifestations are increasingly recognized, affecting up to 40% of patients, and may include:

Recurrent skin infections (eg, abscesses, cellulitis, impetigo, warts)
Eczema, vitiligo, and autoimmune cutaneous disorders [51]
Alopecia areata or universalis, and cutaneous vasculitides such as polyarteritis nodosa [51][53]

Liver involvement, including unexplained hepatomegaly and elevated liver enzymes, is a characteristic feature of the polyclonal infiltration phenotype.[43] Malignancies, particularly gastric carcinoma (risk increased up to 50-fold), and nonHodgkin lymphomas, are serious complications to be screened for regularly.[43][52]

Clinical Phenotypes and Physical Findings

Approximately 80% of patients with CVID present with a single dominant phenotype, while 12.6% display overlapping features.[43] Chapel and colleagues identified the following 5 principal phenotypes of CVID:

Uncomplicated (infection-only)
Autoimmunity
Polyclonal lymphocytic infiltration (eg, lymphoid interstitial pneumonitis, hepatosplenomegaly, granulomas)
Enteropathy (villous atrophy with lymphocytic infiltration)
Lymphoid malignancy [43]

Physical examination may appear normal in early stages but can reveal signs of chronic disease as the condition progresses. Findings may include nasal congestion from chronic sinusitis, scarring of tympanic membranes due to recurrent otitis, or evidence of bronchiectasis such as digital clubbing, crackles, dyspnea, and chronic cough. Additional manifestations include weight loss, night sweats, and fevers—so-called “B symptoms”—in patients with malignancy. Lymphadenopathy, splenomegaly, oral thrush, arthritis, and conjunctivitis may also be detected during evaluation.[54][42][36][48][51]

Evaluation

The evaluation of suspected CVID requires a structured, multistep process that incorporates clinical history, physical examination, laboratory testing, immunophenotyping, functional assays, and, in selected cases, genetic analysis. This approach confirms hypogammaglobulinemia, evaluates immune function, excludes secondary causes, and characterizes phenotypic variability to inform management strategies.[55][56][57][31][58]

A detailed clinical history should document recurrent, severe, or unusual infections—especially those involving the sinopulmonary system—as well as noninfectious manifestations, eg, autoimmune cytopenias, lymphoproliferation, granulomatous disease, gastrointestinal involvement, and skin abnormalities.[55][56][57][59] Physical examination should assess lymphadenopathy, splenomegaly, signs of chronic lung disease (eg, clubbing or crackles), and dermatologic findings, including vitiligo, eczema, or alopecia.[59]

Laboratory Studies

Laboratory testing, primarily the measurement of serum immunoglobulin levels, remains the cornerstone of CVID diagnosis. Patients with CVID typically demonstrate significantly reduced IgG levels, accompanied by low IgA and IgM, with serum IgG often less than 400 mg/dL.[55][59] Routine evaluation includes complete blood counts every 3 to 6 months, Coombs testing for new anemia, and bone marrow biopsy with β2-microglobulin when lymphoma or myelodysplasia is suspected.[59] Additionally, diagnostic assessment of CVID includes evaluation of specific antibody responses. Impaired vaccine responses, measured after administration of protein-based vaccines (tetanus, diphtheria) or polysaccharide vaccines (pneumococcal), further confirm B-cell dysfunction. Isohemagglutinin titers may also be evaluated.[55][56][59]

Flow cytometric immunophenotyping refines evaluation by assessing lymphocyte subsets. Many patients exhibit reduced isotype-switched memory B cells (CD27⁺, IgD⁻, IgM⁻), accompanied by the expansion of CD21^low or transitional B cells. Abnormalities in CD4⁺ T cells, regulatory T cells, and an abnormal CD⁴/CD⁸ ratio may be found in patients with autoimmune or inflammatory features.[55][60][59][60] Classification schemes, eg, EUROclass, link these findings to clinical prognosis.[55][57] Functional assays, including memory B cell ELISpot, may be employed in specialized centers to measure differentiation into antibody-secreting cells.[55][56]

Genetic Testing

Genetic testing, although not required for diagnosis, supports evaluation in patients with early-onset disease, strong family history, or atypical presentations.[55][58][61] Results may identify monogenic defects and help guide prognosis or targeted therapy. Exclusion of secondary causes, eg, protein loss, drug-induced hypogammaglobulinemia, or malignancy, as well as other primary immunodeficiencies, is essential before confirming CVID.[55][56][57][31][58]

System-Specific Evaluation

Following diagnosis, system-specific evaluations are critical. Pulmonary assessment includes spirometry, diffusion studies, blood gas testing, chest radiography, and high-resolution computed tomography (CT) scans at baseline (approximately only 6% of patients have normal findings on high-resolution CT) and every 5 years.[62] Sputum cultures are performed as needed, with repeat testing every 6 to 12 months in patients with bronchiectasis to identify pathogens and determine antibiotic resistance.[63][64] Additionally, lung volume measurement is used to assess restrictive disease in patients who have an intolerance to exercise or who exhibit diffuse parenchymal lung disease on imaging. Bronchoscopy and bronchoalveolar lavage may identify suspected pulmonary granulomas, while magnetic resonance imaging (MRI) may be performed as a radiation-sparing alternative for lung evaluation or when clinically indicated.[59]

Evaluation for lymphoproliferative disease should include abdominal imaging with ultrasound, CT, or MRI, along with lymph node biopsy when lymphoma is suspected.[59] Gastrointestinal assessment includes upper endoscopy with biopsy for Helicobacter pylori infection or malignancy screening at baseline, with repeat studies every 24 months in high-risk patients. Colonoscopy should be performed as indicated, and intestinal biopsies are warranted in patients with malabsorption, chronic diarrhea, or inflammatory symptoms.[59] Neurological evaluation requires a brain MRI and cerebrospinal fluid analysis in patients with suspected infectious or autoimmune neurological disease.[59] Skin or pulmonary biopsies may help exclude autoimmunity or malignancy in patients presenting with nodules, granulomas, or rashes.

Long-Term Surveillance

Long-term monitoring of plasma immunoglobulin levels remains essential: IgG, IgA, and IgM should be measured at diagnosis and every 6 months in patients receiving intravenous immunoglobulin replacement, or every 1 to 3 months in those treated with subcutaneous immunoglobulin replacement.

Treatment / Management

The cornerstone of CVID management involves lifelong immunoglobulin replacement therapy (IGRT), which significantly reduces the frequency and severity of infections, improves quality of life, and prolongs survival. Despite its high cost, IGRT lowers the burden of recurrent infections and their complications.[36][65][66][4][67][68][69]

Immunoglobulin Replacement Therapy

IGRT is indicated in patients with markedly low serum IgG levels, typically more than 2 standard deviations below the normal range, or those who have poor responses to protein and polysaccharide vaccines.[69] Therapy generally begins after the resolution of an active infection, with adequate hydration followed by a slow intravenous infusion load until tolerance develops, and then maintenance dosing is initiated. IVIG is typically administered at 300 to 600 mg/kg every 3 to 4 weeks, while subcutaneous IGRT (SCIG) is usually given weekly or biweekly. Selection depends on tolerability, lifestyle considerations, and access to care.[36][65][66][4][67][68]

Treatment aims to maintain IgG trough levels above 700 to 800 mg/dL, with higher targets for patients with bronchiectasis or persistent infections.[36][65][66][4][67][68] Monitoring requires serum IgG measurement every 6 months, with dose adjustments based on clinical response, body weight, and serum levels.[70] Premedication with antihistamines (eg, diphenhydramine and acetaminophen) and occasionally hydrocortisone helps prevent infusion reactions.[69] Adverse effects from IVIG occur in 20% to 50% of patients, most frequently during the first infusion, and include headache, fever, chills, nausea, thromboembolic events, acute kidney injury, hemolytic anemia, and rarely anaphylaxis. Risk depends on dose, infusion rate, comorbidities, prothrombotic factors, and product brand. SCIG causes fewer systemic reactions but commonly produces local pain and swelling. Hydration and slow infusion rates minimize the risk of complications.[69] Patients with relatively higher IgG levels and only mild impairment of vaccine response may defer IGRT, provided they remain under close follow-up.

Management of Infections

Prompt treatment of bacterial infections is essential, often requiring antibiotic courses 2 to 3 times longer than standard regimens.[69]] Sputum culture or bronchoalveolar lavage should precede the initiation of antibiotics in respiratory infections.[69] Prophylactic antibiotics, such as azithromycin 250 mg 3 times per week, benefit patients with recurrent sinopulmonary infections despite IGRT.[66][71] Antiviral prophylaxis may be indicated during the influenza season for high-risk patients.[69](A1)

Autoimmune and Inflammatory Complications

Autoimmune cytopenias, including immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA), respond first to glucocorticoids. Refractory disease may require rituximab or other immunosuppressants, while splenectomy remains a last-line option.[47][72][73][66][74] Granulomatous-lymphocytic interstitial lung disease (GLILD) often requires corticosteroids; however, steroid-sparing agents, eg, azathioprine, mycophenolate mofetil, rituximab, sirolimus, abatacept, or JAK inhibitors (based on case reports), may be necessary.[74][75] Enteropathy and other inflammatory organ involvement respond to immunosuppressants or biologics tailored to symptoms, with specialist guidance.[75] Rheumatologic conditions are managed according to standard protocols, with IGRT added in immunocompromised patients.[69](B2)

Malignancy Surveillance and Management

Patients with CVID face increased risks of malignancy, particularly lymphoma and gastric carcinoma, which may occur at up to a 50-fold higher rate than in the general population.[52][69][76] Management follows standard oncologic protocols with close collaboration between immunology and oncology teams.[65][66][74] Routine cancer screening should align with national guidelines, although no CVID-specific surveillance schedule has been established. Testing for Helicobacter pylori and pernicious anemia is recommended due to their association with gastric cancer.[52] Hematopoietic stem cell transplantation may be considered in select cases of severe, refractory disease or malignancy.[66][75](B3)

Vaccinations

Vaccination strategies must reflect the degree of antibody deficiency.[77] Inactivated and subunit vaccines are recommended for both mild and severe cases, including DTaP, HBV, HAV, HIB, HPV, influenza, pneumococcal, inactivated polio, meningococcal, anthrax, rabies, intramuscular typhoid, and Japanese encephalitis vaccines. Live-attenuated vaccines are contraindicated in severe deficiencies but may be cautiously considered in mild cases, including MMR, varicella, rotavirus, herpes zoster, smallpox, and BCG. Household contacts should receive all appropriate non-live vaccines to reduce patient exposure risk.[69]

Supportive and Interprofessional Care

Pulmonary complications should be assessed and managed with input from pulmonologists.[69] Patients should not receive blood or blood components without Cytomegalovirus screening. Audiology monitoring helps detect sensorineural hearing loss.[78] Mental health support remains essential to address social isolation and chronic illness burden.[69] Regular dental care is critical, with prophylactic antibiotics required before invasive procedures. Genetic counseling should be offered to families with affected members.[69] Optimal care depends on an interprofessional team, including immunology, pulmonology, hematology, gastroenterology, and infectious disease specialists, working collaboratively to address the wide range of CVID complications and improve long-term outcomes.[65][66][68][69]

Differential Diagnosis

The differential diagnosis of CVID is broad and requires careful clinical, immunological, and, in some cases, genetic assessment. The starting point is the detection of hypogammaglobulinemia, which may be primary or secondary in origin and is not pathognomonic for CVID alone. Therefore, a stepwise exclusion of secondary causes and other primary immunodeficiencies is essential before confirming a CVID diagnosis.

Secondary Hypogammaglobulinemia

Before diagnosing CVID, secondary causes of low immunoglobulin levels must be ruled out, including the following decreased production and increased loss mechanisms:

Decreased production causes
- Immunosuppressive therapies (eg, rituximab, corticosteroids)
- Malignancies (eg, chronic lymphocytic leukemia, multiple myeloma)
- Bone marrow suppression
- Chronic systemic diseases (eg, Goodpasture syndrome) [79][36]
Increased loss causes
- Protein-losing enteropathies
- Nephrotic syndrome
- Extensive burns [79][36]

Other Primary Immunodeficiencies

Several primary immunodeficiency syndromes may present with similar immunologic or clinical features, including:

X-linked agammaglobulinemia (Bruton disease) typically presents in early childhood, characterized by very low levels of immunoglobulins and the absence of B cells.
Hyper-IgM syndromes: present with elevated or normal IgM, but low IgG and IgA.
Selective IgA deficiency and IgG subclass deficiencies often cause recurrent infections, but without fulfilling CVID diagnostic criteria [80]

Monogenic Immunodeficiencies with CVID-Like Phenotypes

Some monogenic defects may clinically mimic CVID, particularly when associated with autoimmunity, enteropathy, or lymphoproliferation. Genetic testing is recommended in cases of early-onset, atypical, or familial disease, eg, CTLA4, LRBA, NFKB1, and NFKB2 mutations.[79][81]

Autoimmune and Lymphoproliferative Disorders

CVID frequently presents with autoimmune cytopenias, enteropathy, or lymphoid hyperplasia, which overlap with systemic autoimmune diseases, including:

Systemic lupus erythematosus
Sjögren’s syndrome
Autoimmune lymphoproliferative syndrome (ALPS)
Other connective tissue disorders [82][5]

Importantly, the absence of autoantibodies (due to impaired antibody production) may obscure the diagnosis of autoimmune diseases in CVID patients.

Gastrointestinal Disorders

CVID-associated enteropathy often mimics other chronic gastrointestinal diseases. Patients may present with features resembling celiac disease, although celiac-specific autoantibodies frequently remain absent. Other differential diagnoses include inflammatory bowel disease and chronic infectious enterocolitis. Histologic evaluation with biopsy may demonstrate nonspecific inflammatory changes rather than pathognomonic findings.[83]

Malignancy

Patients with CVID have a recognized risk of lymphoma, particularly mucosa-associated lymphoid tissue (MALT) lymphoma. This malignancy can complicate CVID or present with clinical features that resemble primary autoimmune or immunodeficiency-related lymphoproliferation, underscoring the need for careful diagnostic distinction.[82][5]

Summary and Diagnostic Strategy

The protean manifestations of CVID—including recurrent infections, autoimmunity, enteropathy, and malignancy—demand a structured and interprofessional diagnostic approach. Essential steps include quantitative measurement of immunoglobulin levels, evaluation of vaccine responses, and flow cytometric analysis of B- and T-cell subsets. Exclusion of secondary causes must remain a priority, while targeted genetic testing should be performed in selected cases.[79][80][84][85][5] Accurate diagnosis depends on integrating clinical features with immunological data and recognizing overlapping presentations to prevent misclassification and optimize management.

Prognosis

The prognosis of CVID is highly variable and depends on multiple factors, including:

Age at diagnosis
Diagnostic delay
Baseline immunoglobulin levels (especially IgA and IgG)
The presence of noninfectious complications, eg, autoimmunity, chronic lung disease, lymphoproliferation, liver disease, and malignancy [67][86][87][8][21][88]

Impact of Immunoglobulin Replacement Therapy

The advent and widespread adoption of IGRT has significantly improved life expectancy in CVID. Before IGRT, survival often fell below 15 years after diagnosis, whereas current series report survival exceeding 50 years for many patients.[67] Deaths due to bacterial infections have declined dramatically with IGRT. Patients who experience only infectious complications demonstrate a 95% lower risk of death compared with those who develop noninfectious manifestations.[8][43]

Noninfectious Complications and Mortality

Despite advances in infection control, noninfectious complications remain the predominant cause of morbidity and mortality, affecting 60% to 70% of patients and contributing to an 11-fold increase in mortality risk.[21] These complications include granulomatous-lymphocytic interstitial lung disease (GLILD), autoimmune cytopenias, and systemic autoimmunity with a prevalence of 25%,[67][86][87][89] chronic liver disease, eg, nodular regenerative hyperplasia and cirrhosis, and malignancies, particularly nonHodgkin lymphoma and gastric cancer.[86][87][90][88][91] Outcomes following liver transplantation in CVID patients remain poor compared with other transplant populations.[86]

Mortality Predictors and Prognostic Scoring

The largest longitudinal cohort of CVID patients (473 individuals followed over 40 years in New York) identified pulmonary complications and malignancy as key predictors of mortality.[8][21][88] Other prognostic factors include:

Higher age at diagnosis
Longer diagnostic delay
Marked reductions in IgA
Low IgG and switched memory B cells, or elevated IgM, all of which correlate with autoimmunity, lymphoid hyperplasia, and pneumonia risk [90][92]

The VISUAL score, a recently developed tool, helps stratify patients at diagnosis by predicting the likelihood of early severe complications and mortality.[93] In pediatric patients, 10-year survival after diagnosis approaches 71%, with worse outcomes observed in those who develop autoimmune disease or malignancies.[89]

Overall Survival

Overall mortality in CVID is estimated at approximately 20% compared with age- and sex-matched controls.[8] Malignant cells in CVID do not demonstrate greater resistance to therapy but appear more prone to dissemination, often necessitating aggressive treatments that may be poorly tolerated.[91] Although uncertainty remains regarding the role of IGRT in preventing noninfectious complications, its established benefit in reducing infectious morbidity has transformed the prognosis of CVID.[92]

Complications

CVID is associated with a broad spectrum of complications, which can be classified as infectious and noninfectious. While recurrent infections are hallmark features and often the first manifestation, noninfectious complications are now recognized as the major contributors to long-term morbidity and mortality.[94][65][5][4] In some patients, complications are the initial clinical presentation, while in others, they emerge later despite early diagnosis and immunoglobulin therapy, potentially shortening life expectancy.

Pulmonary Complications

Pulmonary disease is among the most common and impactful complications of CVID. Patients with respiratory symptoms should undergo evaluation using high-resolution CT to detect any structural abnormalities. The most frequent pulmonary complications include (in descending order of frequency):

Bronchiectasis occurs in about 20% of cases (a structural airway abnormality resulting from recurrent bacterial infections and chronic inflammation) [21]
Bronchospasm
Obstructive and restrictive lung disease
GLILD (often mimics sarcoidosis, and is associated with significant morbidity) [10][95][10]

Autoimmune Complications

Autoimmunity affects approximately 30% to 40% of CVID patients and may represent the first or only clinical feature.[84][96][81] The most frequent autoimmune manifestations include autoimmune cytopenias, eg, immune thrombocytopenia, autoimmune hemolytic anemia, and autoimmune neutropenia.[84][96][81] Additional autoimmune complications that may occur include:

Arthritis, psoriasis, vitiligo
Autoimmune thyroiditis, autoimmune gastritis
Coeliac-like disease
Primary biliary cholangitis [84][81]

Lymphoproliferative and Granulomatous Disorders

Lymphoproliferative and granulomatous disorders frequently complicate CVID and often overlap with autoimmunity. Presentations include persistent lymphadenopathy, splenomegaly, GLILD, and lymphoid hyperplasia.[10]

Gastrointestinal Complications

Gastrointestinal involvement develops in a substantial proportion of patients, ranging from mild to severe. Manifestations include chronic diarrhea, malabsorption, enteropathy with celiac-like features, inflammatory bowel disease (eg, colitis), chronic active or atrophic gastritis, and malignancies, eg, gastric and colorectal cancers, which may present at a younger age than in the general population.[36][97]

Liver Disease

Liver involvement continues to gain recognition in CVID. Nodular regenerative hyperplasia represents a significant complication, often leading to noncirrhotic portal hypertension. Abnormal liver function tests appear in a substantial subset of patients.[10]

Malignancies

CVID patients face a markedly increased risk of malignancy, estimated between 4% and 25%, with an actual incidence of approximately 10%, particularly in adults diagnosed later in life.[98][65][5] NonHodgkin lymphoma occurs in 2% to 8% of patients, most often B-cell type, frequently extranodal, and more common in females older than 30 years.[6][8][65][5][8] Gastric carcinoma also poses a significant risk, often linked to Helicobacter pylori infection and chronic gastritis. These tumors frequently appear as moderately to poorly differentiated intestinal-type adenocarcinomas with dense intra-tumoral lymphocyte infiltration.[97][36] Both lymphoma and gastric carcinoma represent leading causes of mortality in CVID.[94][65][5]

Other Organ-Specific Complications

Widespread immune dysregulation and heterogeneity in CVID contribute to additional complications, including endocrinopathies, neuropathies, and dermatologic disorders, eg, autoimmune and inflammatory skin diseases.[10]

Pathogenesis and Risk Association

The pathogenesis of these diverse complications reflects a multifactorial process involving antibody deficiency, immune dysregulation, cytokine imbalances, and, in some cases, monogenic defects.[10][81] The presence of noninfectious complications—particularly autoimmunity, lymphoproliferation, and malignancy—correlates strongly with poorer prognosis and increased mortality among CVID patients.[94][65][4]

Deterrence and Patient Education

Early diagnosis and lifelong management are key to improving outcomes in patients with CVID. Unfortunately, significant diagnostic delays—often ranging from 4 to 7 years—remain common due to the heterogeneous presentation and lack of awareness among patients and nonspecialist clinicians. Increasing public and clinical education is essential to overcoming these barriers.

Patients and families must be educated that CVID is not a transient or curable condition, but rather a chronic immune disorder requiring consistent follow-up and treatment. Misconceptions about "curing" the disease with antibiotics or short-term therapies should be actively addressed. Clinicians should emphasize that IGRT is the cornerstone of treatment, not only to reduce infection frequency but also to improve long-term survival and quality of life.

Educational initiatives should focus on recognizing early warning signs, eg, recurrent sinus or lung infections, unexplained autoimmune cytopenias, chronic diarrhea, or lymphadenopathy. Clinicians and patients must understand the role of IGRT, including its benefits, potential adverse effects, and the importance of strict adherence to prescribed dosing schedules. Infection prevention requires emphasis through vaccination strategies (excluding live vaccines when clinically appropriate), consistent hand hygiene, and prompt evaluation of new or concerning symptoms.

Family screening or genetic counseling should be encouraged in patients with early-onset disease or those with a family history suggesting immune dysfunction. Counseling must also address psychosocial aspects of chronic immunodeficiency, including potential impacts on education, employment, and emotional well-being. A collaborative care team—comprising immunologists, primary care clinicians, nurses, and mental health professionals—should support patients in understanding their condition and encourage active engagement in their care. Early education and shared decision-making can enhance adherence, reduce complications, and empower patients to maintain healthier lives despite this lifelong disorder.

Pearls and Other Issues

Key factors that should be kept in mind in the management of CVID include:

Delayed recognition of this disease is a common occurrence.
CVID may result from various gene defects.
Opportunistic infections are rare but can occur.
Several causes of hypogammaglobulinemia have to be excluded before determining the diagnosis of CVID.
Higher doses of immune globulin are recommended for those patients with persistent infections.
There is limited evidence of immune globulin therapy and its protective effects against malignancy. However, evidence suggests that treatment can slow the progression of pulmonary disease and reduce the frequency of certain infections. Also, it may offer protection against autoimmunity.

Enhancing Healthcare Team Outcomes

CVID, the most prevalent symptomatic primary immunodeficiency, presents as a complex multisystem disorder with highly heterogeneous manifestations. Patients may experience recurrent sinopulmonary infections, autoimmunity, granulomatous inflammation, gastrointestinal dysfunction, and an increased risk of malignancy. Due to this variability, diagnostic delays often occur, and misdiagnosis remains a common occurrence. Management requires a coordinated, interprofessional approach that integrates early recognition, targeted immunological testing, and long-term monitoring to optimize outcomes, reduce morbidity, and mitigate life-threatening complications.

Physicians and advanced practitioners hold primary responsibility for recognizing clinical warning signs, conducting diagnostic evaluations, and coordinating longitudinal care. Immunologists refine diagnoses through vaccine response assessment, flow cytometry, and genetic testing, while nurses manage immunoglobulin replacement therapy, monitor adverse effects, and provide patient education on infection prevention and home therapy. Pharmacists optimize immunoglobulin dosing, identify potential drug interactions, and assist in planning prophylactic antimicrobial regimens. Mental health professionals, gastroenterologists, pulmonologists, and dietitians address psychosocial stressors, malignancy risk, and systemic complications.

Effective management of CVID requires transparent interprofessional communication, shared decision-making, and structured care coordination. Regular team huddles, shared documentation, and cross-specialty case reviews ensure that subtle complications, such as anemia, chronic cough, or weight loss, are promptly identified. Collaborative oversight of immunoglobulin therapy schedules, vaccination planning, and malignancy surveillance reduces risks and improves safety. By fostering accountability and flattening the care hierarchy, interprofessional teams enhance continuity, minimize medical errors, and empower patients to engage in lifelong care actively.

References

[1]

Szczawińska-Popłonyk A, Ciesielska W, Konarczak M, Opanowski J, Orska A, Wróblewska J, Szczepankiewicz A. Immunogenetic Landscape in Pediatric Common Variable Immunodeficiency. International journal of molecular sciences. 2024 Sep 17:25(18):. doi: 10.3390/ijms25189999. Epub 2024 Sep 17 [PubMed PMID: 39337487]

[2]

Romberg N, Le Coz C. Common variable immunodeficiency, cross currents, and prevailing winds. Immunological reviews. 2024 Mar:322(1):233-243. doi: 10.1111/imr.13291. Epub 2023 Nov 28 [PubMed PMID: 38014621]

[3]

Fekrvand S, Khanmohammadi S, Abolhassani H, Yazdani R. B- and T-Cell Subset Abnormalities in Monogenic Common Variable Immunodeficiency. Frontiers in immunology. 2022:13():912826. doi: 10.3389/fimmu.2022.912826. Epub 2022 Jun 15 [PubMed PMID: 35784324]

[4]

Remiker A, Bolling K, Verbsky J. Common Variable Immunodeficiency. The Medical clinics of North America. 2024 Jan:108(1):107-121. doi: 10.1016/j.mcna.2023.06.012. Epub 2023 Jul 21 [PubMed PMID: 37951645]

[5]

Cunningham-Rundles C. Common variable immune deficiency: case studies. Blood. 2019 Nov 21:134(21):1787-1795. doi: 10.1182/blood.2019002062. Epub [PubMed PMID: 31751486]

Level 3 (low-level) evidence

[6]

Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clinical immunology (Orlando, Fla.). 1999 Jul:92(1):34-48 [PubMed PMID: 10413651]

[7]

Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena MT, Espinosa-Rosales FJ, Hammarström L, Nonoyama S, Quinti I, Routes JM, Tang ML, Warnatz K. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. The journal of allergy and clinical immunology. In practice. 2016 Jan-Feb:4(1):38-59. doi: 10.1016/j.jaip.2015.07.025. Epub 2015 Nov 7 [PubMed PMID: 26563668]

Level 3 (low-level) evidence

[8]

Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012 Feb 16:119(7):1650-7. doi: 10.1182/blood-2011-09-377945. Epub 2011 Dec 16 [PubMed PMID: 22180439]

Level 2 (mid-level) evidence

[9]

Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, Etzioni A, Fischer A, Franco JL, Geha RS, Hammarström L, Nonoyama S, Notarangelo LD, Ochs HD, Puck JM, Roifman CM, Seger R, Tang ML. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Frontiers in immunology. 2011:2():54. doi: 10.3389/fimmu.2011.00054. Epub 2011 Nov 8 [PubMed PMID: 22566844]

[10]

Szczawińska-Popłonyk A, Bekalarska J, Jęch K, Knobloch N, Łukasik O, Ossowska A, Ruducha J, Wysocka Z. The Burden of Non-Infectious Organ-Specific Immunopathology in Pediatric Common Variable Immunodeficiency. International journal of molecular sciences. 2025 Mar 15:26(6):. doi: 10.3390/ijms26062653. Epub 2025 Mar 15 [PubMed PMID: 40141295]

[11]

de Valles-Ibáñez G, Esteve-Solé A, Piquer M, González-Navarro EA, Hernandez-Rodriguez J, Laayouni H, González-Roca E, Plaza-Martin AM, Deyà-Martínez Á, Martín-Nalda A, Martínez-Gallo M, García-Prat M, Del Pino-Molina L, Cuscó I, Codina-Solà M, Batlle-Masó L, Solís-Moruno M, Marquès-Bonet T, Bosch E, López-Granados E, Aróstegui JI, Soler-Palacín P, Colobran R, Yagüe J, Alsina L, Juan M, Casals F. Evaluating the Genetics of Common Variable Immunodeficiency: Monogenetic Model and Beyond. Frontiers in immunology. 2018:9():636. doi: 10.3389/fimmu.2018.00636. Epub 2018 May 14 [PubMed PMID: 29867916]

[12]

Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Franco JL, Gaspar HB, Holland SM, Klein C, Nonoyama S, Ochs HD, Oksenhendler E, Picard C, Puck JM, Sullivan K, Tang ML. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Frontiers in immunology. 2014:5():162. doi: 10.3389/fimmu.2014.00162. Epub 2014 Apr 22 [PubMed PMID: 24795713]

[13]

Bogaert DJ, Dullaers M, Lambrecht BN, Vermaelen KY, De Baere E, Haerynck F. Genes associated with common variable immunodeficiency: one diagnosis to rule them all? Journal of medical genetics. 2016 Sep:53(9):575-90. doi: 10.1136/jmedgenet-2015-103690. Epub 2016 Jun 1 [PubMed PMID: 27250108]

[14]

Chapel H. Common Variable Immunodeficiency Disorders (CVID) - Diagnoses of Exclusion, Especially Combined Immune Defects. The journal of allergy and clinical immunology. In practice. 2016 Nov-Dec:4(6):1158-1159. doi: 10.1016/j.jaip.2016.09.006. Epub [PubMed PMID: 27836061]

[15]

Abolhassani H, Hammarström L, Cunningham-Rundles C. Current genetic landscape in common variable immune deficiency. Blood. 2020 Feb 27:135(9):656-667. doi: 10.1182/blood.2019000929. Epub [PubMed PMID: 31942606]

[16]

Ramirez NJ, Posadas-Cantera S, Caballero-Oteyza A, Camacho-Ordonez N, Grimbacher B. There is no gene for CVID - novel monogenetic causes for primary antibody deficiency. Current opinion in immunology. 2021 Oct:72():176-185. doi: 10.1016/j.coi.2021.05.010. Epub 2021 Jun 19 [PubMed PMID: 34153571]

Level 3 (low-level) evidence

[17]

Nijenhuis T, Klasen I, Weemaes CM, Preijers F, de Vries E, van der Meer JW. Common variable immunodeficiency (CVID) in a family: an autosomal dominant mode of inheritance. The Netherlands journal of medicine. 2001 Sep:59(3):134-9 [PubMed PMID: 11583829]

[18]

Hammarström L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clinical and experimental immunology. 2000 May:120(2):225-31 [PubMed PMID: 10792368]

Level 3 (low-level) evidence

[19]

Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, Viallard JF, Gardembas M, Galicier L, Schleinitz N, Suarez F, Soulas-Sprauel P, Hachulla E, Jaccard A, Gardeur A, Théodorou I, Rabian C, Debré P, DEFI Study Group. Infections in 252 patients with common variable immunodeficiency. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008 May 15:46(10):1547-54. doi: 10.1086/587669. Epub [PubMed PMID: 18419489]

[20]

Tseng CW, Lai KL, Chen DY, Lin CH, Chen HH. The Incidence and Prevalence of Common Variable Immunodeficiency Disease in Taiwan, A Population-Based Study. PloS one. 2015:10(10):e0140473. doi: 10.1371/journal.pone.0140473. Epub 2015 Oct 13 [PubMed PMID: 26461272]

[21]

Gathmann B, Mahlaoui N, CEREDIH, Gérard L, Oksenhendler E, Warnatz K, Schulze I, Kindle G, Kuijpers TW, Dutch WID, van Beem RT, Guzman D, Workman S, Soler-Palacín P, De Gracia J, Witte T, Schmidt RE, Litzman J, Hlavackova E, Thon V, Borte M, Borte S, Kumararatne D, Feighery C, Longhurst H, Helbert M, Szaflarska A, Sediva A, Belohradsky BH, Jones A, Baumann U, Meyts I, Kutukculer N, Wågström P, Galal NM, Roesler J, Farmaki E, Zinovieva N, Ciznar P, Papadopoulou-Alataki E, Bienemann K, Velbri S, Panahloo Z, Grimbacher B, European Society for Immunodeficiencies Registry Working Party. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. The Journal of allergy and clinical immunology. 2014 Jul:134(1):116-26. doi: 10.1016/j.jaci.2013.12.1077. Epub 2014 Feb 28 [PubMed PMID: 24582312]

Level 2 (mid-level) evidence

[22]

Cunningham-Rundles C. Common variable immune deficiency: case studies. Hematology. American Society of Hematology. Education Program. 2019 Dec 6:2019(1):449-456. doi: 10.1182/hematology.2019002062. Epub [PubMed PMID: 31808912]

Level 3 (low-level) evidence

[23]

Roskin KM, Simchoni N, Liu Y, Lee JY, Seo K, Hoh RA, Pham T, Park JH, Furman D, Dekker CL, Davis MM, James JA, Nadeau KC, Cunningham-Rundles C, Boyd SD. IgH sequences in common variable immune deficiency reveal altered B cell development and selection. Science translational medicine. 2015 Aug 26:7(302):302ra135. doi: 10.1126/scitranslmed.aab1216. Epub [PubMed PMID: 26311730]

[24]

Ochtrop ML, Goldacker S, May AM, Rizzi M, Draeger R, Hauschke D, Stehfest C, Warnatz K, Goebel H, Technau-Ihling K, Werner M, Salzer U, Eibel H, Schlesier M, Peter HH. T and B lymphocyte abnormalities in bone marrow biopsies of common variable immunodeficiency. Blood. 2011 Jul 14:118(2):309-18. doi: 10.1182/blood-2010-11-321695. Epub 2011 May 16 [PubMed PMID: 21576700]

Level 2 (mid-level) evidence

[25]

Cunningham-Rundles C, Radigan L, Knight AK, Zhang L, Bauer L, Nakazawa A. TLR9 activation is defective in common variable immune deficiency. Journal of immunology (Baltimore, Md. : 1950). 2006 Feb 1:176(3):1978-87 [PubMed PMID: 16424230]

[26]

Yu JE, Knight AK, Radigan L, Marron TU, Zhang L, Sanchez-Ramón S, Cunningham-Rundles C. Toll-like receptor 7 and 9 defects in common variable immunodeficiency. The Journal of allergy and clinical immunology. 2009 Aug:124(2):349-56, 356.e1-3. doi: 10.1016/j.jaci.2009.05.019. Epub 2009 Jul 9 [PubMed PMID: 19592080]

[27]

Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science (New York, N.Y.). 2002 Dec 13:298(5601):2199-202 [PubMed PMID: 12481138]

[28]

Escobar D, Pons J, Clemente A, Iglesias J, Regueiro V, Bengoechea JA, Matamoros N, Ferrer JM. Defective B cell response to TLR9 ligand (CpG-ODN), Streptococcus pneumoniae and Haemophilus influenzae extracts in common variable immunodeficiency patients. Cellular immunology. 2010:262(2):105-11. doi: 10.1016/j.cellimm.2010.01.002. Epub 2010 Jan 25 [PubMed PMID: 20171611]

Level 3 (low-level) evidence

[29]

Warnatz K, Denz A, Dräger R, Braun M, Groth C, Wolff-Vorbeck G, Eibel H, Schlesier M, Peter HH. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood. 2002 Mar 1:99(5):1544-51 [PubMed PMID: 11861266]

Level 2 (mid-level) evidence

[30]

Piqueras B, Lavenu-Bombled C, Galicier L, Bergeron-van der Cruyssen F, Mouthon L, Chevret S, Debré P, Schmitt C, Oksenhendler E. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. Journal of clinical immunology. 2003 Sep:23(5):385-400 [PubMed PMID: 14601647]

[31]

Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, Vlkova M, Hernandez M, Detkova D, Bos PR, Poerksen G, von Bernuth H, Baumann U, Goldacker S, Gutenberger S, Schlesier M, Bergeron-van der Cruyssen F, Le Garff M, Debré P, Jacobs R, Jones J, Bateman E, Litzman J, van Hagen PM, Plebani A, Schmidt RE, Thon V, Quinti I, Espanol T, Webster AD, Chapel H, Vihinen M, Oksenhendler E, Peter HH, Warnatz K. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008 Jan 1:111(1):77-85 [PubMed PMID: 17898316]

Level 2 (mid-level) evidence

[32]

Sánchez-Ramón S, Radigan L, Yu JE, Bard S, Cunningham-Rundles C. Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clinical immunology (Orlando, Fla.). 2008 Sep:128(3):314-21. doi: 10.1016/j.clim.2008.02.013. Epub 2008 Jul 11 [PubMed PMID: 18620909]

[33]

Carsetti R, Rosado MM, Donnanno S, Guazzi V, Soresina A, Meini A, Plebani A, Aiuti F, Quinti I. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. The Journal of allergy and clinical immunology. 2005 Feb:115(2):412-7 [PubMed PMID: 15696104]

Level 2 (mid-level) evidence

[34]

Ballegaard V, Permin H, Katzenstein TL, Marquart HV, Schejbel L. Long-term follow-up on affinity maturation and memory B-cell generation in patients with common variable immunodeficiency. Journal of clinical immunology. 2013 Aug:33(6):1067-77. doi: 10.1007/s10875-013-9893-2. Epub 2013 May 7 [PubMed PMID: 23649616]

[35]

Horn J, Manguiat A, Berglund LJ, Knerr V, Tahami F, Grimbacher B, Fulcher DA. Decrease in phenotypic regulatory T cells in subsets of patients with common variable immunodeficiency. Clinical and experimental immunology. 2009 Jun:156(3):446-54. doi: 10.1111/j.1365-2249.2009.03913.x. Epub [PubMed PMID: 19438597]

Level 3 (low-level) evidence

[36]

Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, Keller M, Kobrynski LJ, Komarow HD, Mazer B, Nelson RP Jr, Orange JS, Routes JM, Shearer WT, Sorensen RU, Verbsky JW, Bernstein DI, Blessing-Moore J, Lang D, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CR, Schuller D, Spector SL, Tilles S, Wallace D, Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the Joint Council of Allergy, Asthma & Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. The Journal of allergy and clinical immunology. 2015 Nov:136(5):1186-205.e1-78. doi: 10.1016/j.jaci.2015.04.049. Epub 2015 Sep 12 [PubMed PMID: 26371839]

[37]

Fernando SL, Jang HS, Li J. The Immune Dysregulation of Common Variable Immunodeficiency Disorders. Immunology letters. 2021 Feb:230():21-26. doi: 10.1016/j.imlet.2020.12.002. Epub 2020 Dec 14 [PubMed PMID: 33333111]

Level 3 (low-level) evidence

[38]

Wong GK, Millar D, Penny S, Heather JM, Mistry P, Buettner N, Bryon J, Huissoon AP, Cobbold M. Accelerated Loss of TCR Repertoire Diversity in Common Variable Immunodeficiency. Journal of immunology (Baltimore, Md. : 1950). 2016 Sep 1:197(5):1642-9. doi: 10.4049/jimmunol.1600526. Epub 2016 Aug 1 [PubMed PMID: 27481850]

[39]

Malphettes M, Gérard L, Carmagnat M, Mouillot G, Vince N, Boutboul D, Bérezné A, Nove-Josserand R, Lemoing V, Tetu L, Viallard JF, Bonnotte B, Pavic M, Haroche J, Larroche C, Brouet JC, Fermand JP, Rabian C, Fieschi C, Oksenhendler E, DEFI Study Group. Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 Nov 1:49(9):1329-38. doi: 10.1086/606059. Epub [PubMed PMID: 19807277]

[40]

Mahmoudi M, Hedayat M, Aghamohammadi A, Rezaei N. Soluble CD26 and CD30 levels in patients with common variable immunodeficiency. Journal of investigational allergology & clinical immunology. 2013:23(2):120-4 [PubMed PMID: 23654079]

Level 2 (mid-level) evidence

[41]

Cunningham-Rundles C, Radigan L. Deficient IL-12 and dendritic cell function in common variable immune deficiency. Clinical immunology (Orlando, Fla.). 2005 May:115(2):147-53 [PubMed PMID: 15885637]

Level 2 (mid-level) evidence

[42]

Janssen LMA, van der Flier M, de Vries E. Lessons Learned From the Clinical Presentation of Common Variable Immunodeficiency Disorders: A Systematic Review and Meta-Analysis. Frontiers in immunology. 2021:12():620709. doi: 10.3389/fimmu.2021.620709. Epub 2021 Mar 23 [PubMed PMID: 33833753]

Level 1 (high-level) evidence

[43]

Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, Fieschi C, Thon V, Abedi MR, Hammarstrom L. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008 Jul 15:112(2):277-86. doi: 10.1182/blood-2007-11-124545. Epub 2008 Mar 4 [PubMed PMID: 18319398]

Level 2 (mid-level) evidence

[44]

Busse PJ, Farzan S, Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2007 Jan:98(1):1-8; quiz 8-11, 43 [PubMed PMID: 17225714]

[45]

Kainulainen L, Suonpää J, Nikoskelainen J, Svedström E, Vuorinen T, Meurman O, Ruuskanen O. Bacteria and viruses in maxillary sinuses of patients with primary hypogammaglobulinemia. Archives of otolaryngology--head & neck surgery. 2007 Jun:133(6):597-602 [PubMed PMID: 17576911]

Level 2 (mid-level) evidence

[46]

Cadranel J, Bouvry D, Wislez M. [Respiratory manifestations of common variable immunodeficiency in adults]. Revue des maladies respiratoires. 2003 Feb:20(1 Pt 1):126-33 [PubMed PMID: 12709641]

[47]

Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). Journal of autoimmunity. 2005 Aug:25(1):57-62 [PubMed PMID: 15994061]

Level 2 (mid-level) evidence

[48]

Patuzzo G, Barbieri A, Tinazzi E, Veneri D, Argentino G, Moretta F, Puccetti A, Lunardi C. Autoimmunity and infection in common variable immunodeficiency (CVID). Autoimmunity reviews. 2016 Sep:15(9):877-82. doi: 10.1016/j.autrev.2016.07.011. Epub 2016 Jul 6 [PubMed PMID: 27392505]

[49]

Swierkot J, Lewandowicz-Uszynska A, Chlebicki A, Szmyrka-Kaczmarek M, Polańska B, Jankowski A, Szechinski J. Rheumatoid arthritis in a patient with common variable immunodeficiency: difficulty in diagnosis and therapy. Clinical rheumatology. 2006 Feb:25(1):92-4 [PubMed PMID: 15940551]

Level 3 (low-level) evidence

[50]

Fernández-Castro M, Mellor-Pita S, Citores MJ, Muñoz P, Tutor-Ureta P, Silva L, Vargas JA, Yebra-Bango M, Andreu JL. Common variable immunodeficiency in systemic lupus erythematosus. Seminars in arthritis and rheumatism. 2007 Feb:36(4):238-45 [PubMed PMID: 17276173]

Level 3 (low-level) evidence

[51]

Zarezadeh Mehrabadi A, Aghamohamadi N, Abolhassani H, Aghamohammadi A, Rezaei N, Yazdani R. Comprehensive Assessment of Skin Disorders in Patients with Common Variable Immunodeficiency (CVID). Journal of clinical immunology. 2022 Apr:42(3):653-664. doi: 10.1007/s10875-022-01211-x. Epub 2022 Jan 27 [PubMed PMID: 35084691]

[52]

Dhalla F, da Silva SP, Lucas M, Travis S, Chapel H. Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme. Clinical and experimental immunology. 2011 Jul:165(1):1-7. doi: 10.1111/j.1365-2249.2011.04384.x. Epub 2011 Apr 6 [PubMed PMID: 21470209]

[53]

Pagnini I, Simonini G, Lippi F, Azzari C, Cimaz R. Cutaneous polyarteritis nodosa and common variable immunodeficiency: a previously unreported association. Clinical and experimental rheumatology. 2012 Jan-Feb:30(1 Suppl 70):S169 [PubMed PMID: 22260879]

Level 3 (low-level) evidence

[54]

Urschel S, Kayikci L, Wintergerst U, Notheis G, Jansson A, Belohradsky BH. Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation. The Journal of pediatrics. 2009 Jun:154(6):888-94. doi: 10.1016/j.jpeds.2008.12.020. Epub 2009 Feb 23 [PubMed PMID: 19230900]

[55]

Wang LA, Abbott JK. "Common variable immunodeficiency: Challenges for diagnosis". Journal of immunological methods. 2022 Oct:509():113342. doi: 10.1016/j.jim.2022.113342. Epub 2022 Aug 24 [PubMed PMID: 36027932]

[56]

Lee TK, Gereige JD, Maglione PJ. State-of-the-art diagnostic evaluation of common variable immunodeficiency. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2021 Jul:127(1):19-27. doi: 10.1016/j.anai.2021.03.005. Epub 2021 Mar 11 [PubMed PMID: 33716149]

[57]

Rösel AL, Scheibenbogen C, Schliesser U, Sollwedel A, Hoffmeister B, Hanitsch L, von Bernuth H, Krüger R, Warnatz K, Volk HD, Thomas S. Classification of common variable immunodeficiencies using flow cytometry and a memory B-cell functionality assay. The Journal of allergy and clinical immunology. 2015 Jan:135(1):198-208. doi: 10.1016/j.jaci.2014.06.022. Epub 2014 Aug 10 [PubMed PMID: 25112698]

[58]

Ameratunga R, Brewerton M, Slade C, Jordan A, Gillis D, Steele R, Koopmans W, Woon ST. Comparison of diagnostic criteria for common variable immunodeficiency disorder. Frontiers in immunology. 2014:5():415. doi: 10.3389/fimmu.2014.00415. Epub 2014 Sep 15 [PubMed PMID: 25309532]

[59]

Salzer U, Warnatz K, Peter HH. Common variable immunodeficiency: an update. Arthritis research & therapy. 2012 Sep 24:14(5):223. doi: 10.1186/ar4032. Epub 2012 Sep 24 [PubMed PMID: 23043756]

[60]

Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini C, Claudio P, Franco D, Maria Pesce A, Borghese F, Guerra A, Rondelli R, Plebani A, Italian Primary Immunodeficiency Network. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. Journal of clinical immunology. 2007 May:27(3):308-16 [PubMed PMID: 17510807]

Level 2 (mid-level) evidence

[61]

Orange JS, Glessner JT, Resnick E, Sullivan KE, Lucas M, Ferry B, Kim CE, Hou C, Wang F, Chiavacci R, Kugathasan S, Sleasman JW, Baldassano R, Perez EE, Chapel H, Cunningham-Rundles C, Hakonarson H. Genome-wide association identifies diverse causes of common variable immunodeficiency. The Journal of allergy and clinical immunology. 2011 Jun:127(6):1360-7.e6. doi: 10.1016/j.jaci.2011.02.039. Epub 2011 Apr 17 [PubMed PMID: 21497890]

Level 2 (mid-level) evidence

[62]

Cinetto F, Scarpa R, Rattazzi M, Agostini C. The broad spectrum of lung diseases in primary antibody deficiencies. European respiratory review : an official journal of the European Respiratory Society. 2018 Sep 30:27(149):. doi: 10.1183/16000617.0019-2018. Epub 2018 Aug 29 [PubMed PMID: 30158276]

[63]

Rich AL, Le Jeune IR, McDermott L, Kinnear WJ. Serial lung function tests in primary immune deficiency. Clinical and experimental immunology. 2008 Jan:151(1):110-3 [PubMed PMID: 18005259]

[64]

Stafler P, Carr SB. Non-cystic fibrosis bronchiectasis: its diagnosis and management. Archives of disease in childhood. Education and practice edition. 2010 Jun:95(3):73-82. doi: 10.1136/adc.2007.130054. Epub [PubMed PMID: 20501530]

[65]

Gupta S, Pattanaik D, Krishnaswamy G. Common Variable Immune Deficiency and Associated Complications. Chest. 2019 Sep:156(3):579-593. doi: 10.1016/j.chest.2019.05.009. Epub 2019 May 22 [PubMed PMID: 31128118]

[66]

Szaflarska A, Lenart M, Rutkowska-Zapała M, Siedlar M. Clinical and experimental treatment of primary humoral immunodeficiencies. Clinical and experimental immunology. 2024 Apr 23:216(2):120-131. doi: 10.1093/cei/uxae008. Epub [PubMed PMID: 38306460]

[67]

Park K, Wang Q, Lee RU. Navigating the management complexity in long-term asymptomatic immunodeficiency. Allergy and asthma proceedings. 2023 Nov 1:44(6):436-439. doi: 10.2500/aap.2023.44.230054. Epub [PubMed PMID: 37919850]

[68]

Detková D, Español T. An update on treatment strategies for common variable immunodeficiency. Expert review of clinical immunology. 2009 Jul:5(4):381-90. doi: 10.1586/eci.09.22. Epub [PubMed PMID: 20477035]

[69]

Cunningham-Rundles C. How I treat common variable immune deficiency. Blood. 2010 Jul 8:116(1):7-15. doi: 10.1182/blood-2010-01-254417. Epub 2010 Mar 23 [PubMed PMID: 20332369]

[70]

Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. The Journal of allergy and clinical immunology. 2010 Jun:125(6):1354-1360.e4. doi: 10.1016/j.jaci.2010.02.040. Epub 2010 May 14 [PubMed PMID: 20471071]

[71]

Milito C, Pulvirenti F, Cinetto F, Lougaris V, Soresina A, Pecoraro A, Vultaggio A, Carrabba M, Lassandro G, Plebani A, Spadaro G, Matucci A, Fabio G, Dellepiane RM, Martire B, Agostini C, Abeni D, Tabolli S, Quinti I. Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies. The Journal of allergy and clinical immunology. 2019 Aug:144(2):584-593.e7. doi: 10.1016/j.jaci.2019.01.051. Epub 2019 Mar 22 [PubMed PMID: 30910492]

Level 1 (high-level) evidence

[72]

Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, Dechartres A, Berezne A, Bonnotte B, DeRevel T, Auzary C, Jaussaud R, Larroche C, LeQuellec A, Ruivard M, Seve P, Smail A, Viallard JF, Godeau B, Hermine O, Michel M. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. British journal of haematology. 2011 Nov:155(4):498-508. doi: 10.1111/j.1365-2141.2011.08880.x. Epub 2011 Oct 8 [PubMed PMID: 21981575]

Level 2 (mid-level) evidence

[73]

Sève P, Bourdillon L, Sarrot-Reynauld F, Ruivard M, Jaussaud R, Bouhour D, Bonotte B, Gardembas M, Poindron V, Thiercelin MF, Broussolle C, Oksenhendler E, DEF-I Study Group. Autoimmune hemolytic anemia and common variable immunodeficiency: a case-control study of 18 patients. Medicine. 2008 May:87(3):177-184. doi: 10.1097/MD.0b013e31817a90ba. Epub [PubMed PMID: 18520327]

Level 2 (mid-level) evidence

[74]

Fevang B. Treatment of inflammatory complications in common variable immunodeficiency (CVID): current concepts and future perspectives. Expert review of clinical immunology. 2023 Jun:19(6):627-638. doi: 10.1080/1744666X.2023.2198208. Epub 2023 Apr 6 [PubMed PMID: 36996348]

Level 3 (low-level) evidence

[75]

Bonilla FA. Personalized therapy for common variable immunodeficiency. Allergy and asthma proceedings. 2020 Jan 1:41(1):19-25. doi: 10.2500/aap.2020.41.190012. Epub [PubMed PMID: 31888779]

[76]

van der Poorten DK, McLeod D, Ahlenstiel G, Read S, Kwok A, Santhakumar C, Bassan M, Culican S, Campbell D, Wong SWJ, Evans L, Jideh B, Kane A, Katelaris CH, Keat K, Ko Y, Lee JA, Limaye S, Lin MW, Murad A, Rafferty M, Suan D, Swaminathan S, Riminton SD, Toong C, Berglund LJ. Gastric Cancer Screening in Common Variable Immunodeficiency. Journal of clinical immunology. 2018 Oct:38(7):768-777. doi: 10.1007/s10875-018-0546-3. Epub 2018 Sep 15 [PubMed PMID: 30219982]

[77]

Sobh A, Bonilla FA. Vaccination in Primary Immunodeficiency Disorders. The journal of allergy and clinical immunology. In practice. 2016 Nov-Dec:4(6):1066-1075. doi: 10.1016/j.jaip.2016.09.012. Epub [PubMed PMID: 27836056]

[78]

Berlucchi M, Soresina A, Redaelli De Zinis LO, Valetti L, Valotti R, Lougaris V, Meini A, Salsi D, Nicolai P, Plebani A. Sensorineural hearing loss in primary antibody deficiency disorders. The Journal of pediatrics. 2008 Aug:153(2):293-6. doi: 10.1016/j.jpeds.2008.03.008. Epub [PubMed PMID: 18639734]

[79]

Yazdanpanah N, Rezaei N. Autoimmune disorders associated with common variable immunodeficiency: prediction, diagnosis, and treatment. Expert review of clinical immunology. 2022 Dec:18(12):1265-1283. doi: 10.1080/1744666X.2022.2132938. Epub 2022 Oct 17 [PubMed PMID: 36197300]

[80]

Filion CA, Taylor-Black S, Maglione PJ, Radigan L, Cunningham-Rundles C. Differentiation of Common Variable Immunodeficiency From IgG Deficiency. The journal of allergy and clinical immunology. In practice. 2019 Apr:7(4):1277-1284. doi: 10.1016/j.jaip.2018.12.004. Epub 2018 Dec 14 [PubMed PMID: 30557717]

[81]

Chawla S, Barman P, Tyagi R, Jindal AK, Sharma S, Rawat A, Singh S. Autoimmune Cytopenias in Common Variable Immunodeficiency Are a Diagnostic and Therapeutic Conundrum: An Update. Frontiers in immunology. 2022:13():869466. doi: 10.3389/fimmu.2022.869466. Epub 2022 Jun 20 [PubMed PMID: 35795667]

[82]

Quartuccio L, De Marchi G, Longhino S, Manfrè V, Rizzo MT, Gandolfo S, Tommasini A, De Vita S, Fox R. Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjögren's Syndrome: Clues for a Personalized Medicine. Frontiers in immunology. 2021:12():703780. doi: 10.3389/fimmu.2021.703780. Epub 2021 Jul 12 [PubMed PMID: 34322134]

[83]

Sanchez DA, Rotella K, Toribio C, Hernandez M, Cunningham-Rundles C. Characterization of infectious and non-infectious gastrointestinal disease in common variable immunodeficiency: analysis of 114 patient cohort. Frontiers in immunology. 2023:14():1209570. doi: 10.3389/fimmu.2023.1209570. Epub 2023 Aug 30 [PubMed PMID: 37711607]

[84]

Mormile I, Punziano A, Riolo CA, Granata F, Williams M, de Paulis A, Spadaro G, Rossi FW. Common Variable Immunodeficiency and Autoimmune Diseases: A Retrospective Study of 95 Adult Patients in a Single Tertiary Care Center. Frontiers in immunology. 2021:12():652487. doi: 10.3389/fimmu.2021.652487. Epub 2021 Jul 5 [PubMed PMID: 34290696]

Level 2 (mid-level) evidence

[85]

Lenti MV, Savioli J, Achilli G, Di Sabatino A. Autoimmune diseases associated with common variable immune deficiency. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2020 Nov:31 Suppl 26():60-62. doi: 10.1111/pai.13339. Epub [PubMed PMID: 33236426]

[86]

Song J, Lleo A, Yang GX, Zhang W, Bowlus CL, Gershwin ME, Leung PSC. Common Variable Immunodeficiency and Liver Involvement. Clinical reviews in allergy & immunology. 2018 Dec:55(3):340-351. doi: 10.1007/s12016-017-8638-z. Epub [PubMed PMID: 28785926]

[87]

Azzu V, Elias JE, Duckworth A, Davies S, Brais R, Kumararatne DS, Gimson AES, Griffiths WJH. Liver transplantation in adults with liver disease due to common variable immunodeficiency leads to early recurrent disease and poor outcome. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2018 Feb:24(2):171-181. doi: 10.1002/lt.24979. Epub [PubMed PMID: 29156507]

[88]

Odnoletkova I, Kindle G, Quinti I, Grimbacher B, Knerr V, Gathmann B, Ehl S, Mahlaoui N, Van Wilder P, Bogaerts K, de Vries E, Plasma Protein Therapeutics Association (PPTA) Taskforce. The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data. Orphanet journal of rare diseases. 2018 Nov 12:13(1):201. doi: 10.1186/s13023-018-0941-0. Epub 2018 Nov 12 [PubMed PMID: 30419968]

Level 2 (mid-level) evidence

[89]

Mohammadinejad P, Aghamohammadi A, Abolhassani H, Sadaghiani MS, Abdollahzade S, Sadeghi B, Soheili H, Tavassoli M, Fathi SM, Tavakol M, Behniafard N, Darabi B, Pourhamdi S, Rezaei N. Pediatric patients with common variable immunodeficiency: long-term follow-up. Journal of investigational allergology & clinical immunology. 2012:22(3):208-14 [PubMed PMID: 22697011]

[90]

Graziano V, Pecoraro A, Mormile I, Quaremba G, Genovese A, Buccelli C, Paternoster M, Spadaro G. Delay in diagnosis affects the clinical outcome in a cohort of cvid patients with marked reduction of iga serum levels. Clinical immunology (Orlando, Fla.). 2017 Jul:180():1-4. doi: 10.1016/j.clim.2017.03.011. Epub 2017 Mar 25 [PubMed PMID: 28347823]

Level 2 (mid-level) evidence

[91]

Shapiro RS. Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists. American journal of hematology. 2011 Jan:86(1):48-55. doi: 10.1002/ajh.21903. Epub [PubMed PMID: 21120868]

[92]

Gregersen S, Aaløkken TM, Mynarek G, Fevang B, Holm AM, Ueland T, Aukrust P, Kongerud J, Johansen B, Frøland SS. Development of pulmonary abnormalities in patients with common variable immunodeficiency: associations with clinical and immunologic factors. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2010 Jun:104(6):503-10. doi: 10.1016/j.anai.2010.04.015. Epub [PubMed PMID: 20568383]

Level 2 (mid-level) evidence

[93]

Guevara-Hoyer K, Jiménez-Huete A, Vasconcelos J, Neves E, Sánchez-Ramón S. Variable immunodeficiency score upfront analytical link (VISUAL), a proposal for combined prognostic score at diagnosis of common variable immunodeficiency. Scientific reports. 2021 Jun 9:11(1):12211. doi: 10.1038/s41598-021-91791-2. Epub 2021 Jun 9 [PubMed PMID: 34108596]

[94]

Abyazi ML, Bell KA, Gyimesi G, Baker TS, Byun M, Ko HM, Cunningham-Rundles C, Feng F, Maglione PJ. Convergence of cytokine dysregulation and antibody deficiency in common variable immunodeficiency with inflammatory complications. The Journal of allergy and clinical immunology. 2022 Jan:149(1):315-326.e9. doi: 10.1016/j.jaci.2021.06.008. Epub 2021 Jun 17 [PubMed PMID: 34146579]

[95]

Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmunity reviews. 2006 Feb:5(2):156-9 [PubMed PMID: 16431351]

Level 3 (low-level) evidence

[96]

Cunningham-Rundles C, Casanova JL, Boisson B. Common variable immunodeficiency: autoimmune cytopenias and advances in molecular diagnosis. Hematology. American Society of Hematology. Education Program. 2024 Dec 6:2024(1):137-142. doi: 10.1182/hematology.2024000538. Epub [PubMed PMID: 39643993]

Level 3 (low-level) evidence

[97]

Leone P, Vacca A, Dammacco F, Racanelli V. Common Variable Immunodeficiency and Gastric Malignancies. International journal of molecular sciences. 2018 Feb 2:19(2):. doi: 10.3390/ijms19020451. Epub 2018 Feb 2 [PubMed PMID: 29393912]

[98]

Tak Manesh A, Azizi G, Heydari A, Kiaee F, Shaghaghi M, Hossein-Khannazer N, Yazdani R, Abolhassani H, Aghamohammadi A. Epidemiology and pathophysiology of malignancy in common variable immunodeficiency? Allergologia et immunopathologia. 2017 Nov-Dec:45(6):602-615. doi: 10.1016/j.aller.2017.01.006. Epub 2017 Apr 12 [PubMed PMID: 28411962]